<p>Tufton Capital Management 在最近向证券交易委员会的披露中表示，在第三季度将其在礼来公司（NYSE:LLY - 免费报告）的持股比例提高了 20.8%。该机构投资者在此期间购买了 986 股后，持有该公司 5,732 股股票。截至其最近向证券交易委员会的备案，Tufton Capital Management 在礼来公司的持股价值为 4,373,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>2026 年看起来像 “必胜” 赢家的 3 只生物科技股票</li>
</ul>
<p>其他几家机构投资者和对冲基金也调整了他们对 LLY 的持股。Harvey Capital Management Inc. 在第三季度购买了礼来公司的新股份，价值为 5,098,000 美元。Avantax Planning Partners Inc. 在第三季度将其在礼来公司的股份提高了 8.3%。Avantax Planning Partners Inc. 现在拥有 6,037 股该公司的股票，价值为 4,606,000 美元，此前在上个季度又购买了 463 股。Sovran Advisors LLC 在第三季度将其在礼来公司的持股提高了 26.4%。Sovran Advisors LLC 现在拥有 2,112 股该公司的股票，价值为 1,783,000 美元，此前在此期间又购买了 441 股。Patron Partners LLC 在第三季度将其在礼来公司的股份提高了 30.0%。Patron Partners LLC 现在拥有 5,158 股该公司的股票，价值为 3,936,000 美元，此前在上个季度又收购了 1,190 股。最后，OneAscent Family Office LLC 在第三季度将其在礼来公司的持股提高了 3.0%。OneAscent Family Office LLC 现在拥有 551 股该公司的股票，价值为 420,000 美元，此前在此期间又收购了 16 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师升级和降级</h2>
<p>一些研究分析师最近对该公司发表了看法。Sanford C. Bernstein 在 12 月 19 日的研究报告中重申了对礼来公司股票的 “跑赢大盘” 评级。Guggenheim 将礼来公司的股票目标价从 1,163.00 美元下调至 1,161.00 美元，并在 1 月 20 日的报告中给予该公司 “买入” 评级。富国银行在 12 月 10 日的研究报告中将礼来公司的目标价从 1,100.00 美元提高至 1,200.00 美元，并给予该股票 “超配” 评级。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Jefferies Financial Group 在 1 月 8 日的报告中将礼来公司的目标价从 976.00 美元提高至 1,300.00 美元，并给予该股票 “买入” 评级。四位投资分析师对该股票给予了强烈买入评级，十八位给予了买入评级，四位对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，礼来公司目前的共识评级为 “买入”，平均目标价为 1,174.61 美元。</p>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
<p><strong>获取我们对礼来公司的最新分析</strong></p>
<h2>礼来公司股票表现</h2>
<p>礼来公司（NYSE:LLY）周一开盘价为 1,065.05 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.11，市盈率增长比率为 0.80，贝塔值为 0.35。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。该股票的 50 日移动平均价格为 1,057.19 美元，200 日移动平均价格为 881.44 美元。</p>
<ul>
<li>一只长期投资者不应忽视的新 IPO</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了其财报。该公司报告第三季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司第三季度的收入为 176 亿美元，而一致预期为 160.9 亿美元。在去年同期，该公司每股收益为 1.18 美元。该公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。分析师预测礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司还最近宣布了一项季度股息，将于 3 月 10 日支付。2 月 13 日的股东将获得每股 1.73 美元的股息。除息日期为 2 月 13 日。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率目前为 29.35%。</p>
<h2>礼来公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>在星期一上午 9:30 购买这只股票！</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>特朗普计划利用公共法第 63-43 条：请提前准备</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Tufton Capital Management 在第三季度将其在礼来公司（NYSE: LLY）的持股增加了 20.8%，额外购买了 986 股，总持股达到 5,732 股，价值为 437 万美元。其他机构投资者也调整了他们的持股，其中哈维资本管理和帕特农合伙人显著增加了持股。分析师对礼来的前景保持乐观，普遍评级为 “买入”，平均目标价为 1,174.61 美元。该股票开盘价为 1,065.05 美元，市值为 1.01 万亿美元，最近的财报显示出强劲的表现</p>

<p>Tufton Capital Management raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,732 shares of the company's stock after buying an additional 986 shares during the period. Tufton Capital Management's holdings in Eli Lilly and Company were worth $4,373,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Tufton Capital Management 在最近向证券交易委员会的披露中表示，在第三季度将其在礼来公司（NYSE:LLY - 免费报告）的持股比例提高了 20.8%。该机构投资者在此期间购买了 986 股后，持有该公司 5,732 股股票。截至其最近向证券交易委员会的备案，Tufton Capital Management 在礼来公司的持股价值为 4,373,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年看起来像 “必胜” 赢家的 3 只生物科技股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also modified their holdings of LLY. Harvey Capital Management Inc. bought a new stake in shares of Eli Lilly and Company during the third quarter worth $5,098,000. Avantax Planning Partners Inc. raised its stake in shares of Eli Lilly and Company by 8.3% during the third quarter. Avantax Planning Partners Inc. now owns 6,037 shares of the company's stock worth $4,606,000 after buying an additional 463 shares during the last quarter. Sovran Advisors LLC lifted its holdings in Eli Lilly and Company by 26.4% in the third quarter. Sovran Advisors LLC now owns 2,112 shares of the company's stock valued at $1,783,000 after buying an additional 441 shares during the period. Patron Partners LLC boosted its stake in Eli Lilly and Company by 30.0% in the third quarter. Patron Partners LLC now owns 5,158 shares of the company's stock valued at $3,936,000 after acquiring an additional 1,190 shares during the last quarter. Finally, OneAscent Family Office LLC grew its holdings in Eli Lilly and Company by 3.0% during the 3rd quarter. OneAscent Family Office LLC now owns 551 shares of the company's stock worth $420,000 after acquiring an additional 16 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金也调整了他们对 LLY 的持股。Harvey Capital Management Inc. 在第三季度购买了礼来公司的新股份，价值为 5,098,000 美元。Avantax Planning Partners Inc. 在第三季度将其在礼来公司的股份提高了 8.3%。Avantax Planning Partners Inc. 现在拥有 6,037 股该公司的股票，价值为 4,606,000 美元，此前在上个季度又购买了 463 股。Sovran Advisors LLC 在第三季度将其在礼来公司的持股提高了 26.4%。Sovran Advisors LLC 现在拥有 2,112 股该公司的股票，价值为 1,783,000 美元，此前在此期间又购买了 441 股。Patron Partners LLC 在第三季度将其在礼来公司的股份提高了 30.0%。Patron Partners LLC 现在拥有 5,158 股该公司的股票，价值为 3,936,000 美元，此前在上个季度又收购了 1,190 股。最后，OneAscent Family Office LLC 在第三季度将其在礼来公司的持股提高了 3.0%。OneAscent Family Office LLC 现在拥有 551 股该公司的股票，价值为 420,000 美元，此前在此期间又收购了 16 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of research analysts have recently weighed in on the company. Sanford C. Bernstein reissued an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 20th. Wells Fargo &amp; Company raised their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Jefferies Financial Group increased their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, January 8th. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of &#34;Buy&#34; and an average target price of $1,174.61.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司发表了看法。Sanford C. Bernstein 在 12 月 19 日的研究报告中重申了对礼来公司股票的 “跑赢大盘” 评级。Guggenheim 将礼来公司的股票目标价从 1,163.00 美元下调至 1,161.00 美元，并在 1 月 20 日的报告中给予该公司 “买入” 评级。富国银行在 12 月 10 日的研究报告中将礼来公司的目标价从 1,100.00 美元提高至 1,200.00 美元，并给予该股票 “超配” 评级。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Jefferies Financial Group 在 1 月 8 日的报告中将礼来公司的目标价从 976.00 美元提高至 1,300.00 美元，并给予该股票 “买入” 评级。四位投资分析师对该股票给予了强烈买入评级，十八位给予了买入评级，四位对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，礼来公司目前的共识评级为 “买入”，平均目标价为 1,174.61 美元。</p>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？这个 ETF 包含了它们所有。</li>
</ul>
</div><p><strong>Get Our Latest Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们对礼来公司的最新分析</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><p>Shares of NYSE LLY opened at $1,065.05 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The stock has a market capitalization of $1.01 trillion, a PE ratio of 52.11, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a 50 day moving average price of $1,057.19 and a 200 day moving average price of $881.44.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY）周一开盘价为 1,065.05 美元。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,133.95 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.11，市盈率增长比率为 0.80，贝塔值为 0.35。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。该股票的 50 日移动平均价格为 1,057.19 美元，200 日移动平均价格为 881.44 美元。</p>
</div><ul>
<li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>一只长期投资者不应忽视的新 IPO</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the company earned $1.18 earnings per share. The firm's revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日发布了其财报。该公司报告第三季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司第三季度的收入为 176 亿美元，而一致预期为 160.9 亿美元。在去年同期，该公司每股收益为 1.18 美元。该公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。分析师预测礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 3 月 10 日支付。2 月 13 日的股东将获得每股 1.73 美元的股息。除息日期为 2 月 13 日。这代表着每年 6.92 美元的股息和 0.6% 的股息收益率。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率目前为 29.35%。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
<li>Trump Planning to Use Public Law 63-43: Prepare Now</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>在星期一上午 9:30 购买这只股票！</li>
<li>什么费用可以从资本利得税中扣除？</li>
<li>特朗普计划利用公共法第 63-43 条：请提前准备</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中有买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tufton Capital Management Purchases 986 Shares of Eli Lilly and Company $LLY

Market Beat

礼来

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

Invesco Nasdaq Biotechnology ETF

1 倍做空 LLY ETF - Direxion

基因改革 ETF - ARK

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

2 倍做多 LLY ETF - Direxion

2 倍做多 LLY ETF - Defiance

标普全球医疗股指数 ETF - iShares

Tufton Capital Management 购入了 986 股礼来公司（Eli Lilly）的股票，代码为$LLY